Jefferies raised the firm’s price target on Novartis to $122.50 from $121 and keeps a Buy rating on the shares. The firm’s Q2 sales forecast is 2% above consensus and it sees 6%-8% higher profits, which “may enable another beat-and-raise,” the analyst tells investors in a preview note for the EU pharma group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- MorphoSys and Novartis sign delisting agreement
- Novartis announces its Phase III study of Scemblix showed ‘superior efficacy’
- Novartis says Phase III data confirm efficacy, safety of oral remibrutinib
- PayPal upgraded, UiPath downgraded: Wall Street’s top analyst calls
- Novartis initiated with a Buy at Goldman Sachs